Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens

Anti-Cancer Drugs

Volumn 13, Issue 1, 2002, Pages 101-110

  Würthwein, Gudrun ^a   Klingebiel, Thomas ^a   Krümpelmann, Sebastian ^a   Metz, Melanie ^a   Schwenker, Kerstin ^a   Kranz, Karen ^a   Lanvers, Claudia ^a   Boos, Joachim ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Bone marrow transplantation; Children; Etoposide; High dose; P Pharm; Population pharmacokinetics

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; THIOTEPA;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DRUG BINDING; DRUG CLEARANCE; ELECTROCHEMICAL ANALYSIS; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MODEL; NEUROBLASTOMA; POPULATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; FEMALE; HALF-LIFE; HUMANS; INFANT; MALE; NEOPLASMS; PROTEIN BINDING; TRANSPLANTATION CONDITIONING;

EID: 0036183674     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200201000-00012     Document Type: Article

References (30)

1. Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature
2. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation
3. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma
4. The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer
5. Steady-state levels and bone marrow toxicity of etoposide in children and infants: Does etoposide require age-dependent dose calculation?
6. Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed?
7. Presenting and reporting pharmacokinetic data
8. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer
9. Pharmacokinetics of high dose etoposide (VP 16-213)
10. Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies
11. Pharmacokinetics of high-dose VP-16: 6-Hour infusion versus 34-hour infusion
12. The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation
13. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors
14. Pharmacokinetics of high-dose etoposide after short-term infusion
15. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
16. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
17. Etoposide infusions for treatment of metastatic lung cancer
18. Pharmacokinetics of high-dose etoposide
19. Disposition of total and unbound etoposide following high-dose therapy
20. The effect of etoposide on human CFU-GM
21. When is autologous bone marrow transplantation safe after high-dose treatment with etoposide?
22. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A
23. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children
24. Relation of systemic exposure to unbound etoposide and hematologic toxicity
25. Pharmacokinetic aspects of oral administration of etoposide
26. Etoposide protein binding in cancer patients
27. Population pharmacokinetics of total and unbound etoposide
28. Altered protein binding of etoposide in patients with cancer
29. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction
30. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule